Video
Dr. Welslau on the Rationale for the REFLECT Trial in DLBCL
Author(s):
Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the rationale for the REFLECT trial in diffuse large B-cell lymphoma.
Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the rationale for the prospective, multicenter, open-label REFLECT trial in diffuse large B-cell lymphoma (DLBCL).
In 2017, the European Medicines Agency approved Rixathon (SDZ-RTX), a Sandoz biosimilar for rituximab (Rituxan) for the same indications as the reference product. In August 29, 2017, data from the ASSIST-FL trial, published in Lancet Haematology, demonstrated the similarity of the biosimilar to the reference biologic in patients with follicular lymphoma.
The REFLECT trial was launched after the approval of the biosimilar to evaluate its efficacy as a curative therapy in combination with CHOP (cyclophosphamide, doxorubicin, hydrochloride, vincristine sulfate, and prednisone) in patients with previously untreated CD20-positive DLBCL, says Welslau. The trial sought to the confirm the similarity of the Sandoz biosimilar to reference biologic in this patient population.
